131 related articles for article (PubMed ID: 33165851)
1. Human T-ALL Xenografts.
Fuentes P; Toribio ML; González-García S
Methods Mol Biol; 2021; 2185():215-239. PubMed ID: 33165851
[TBL] [Abstract][Full Text] [Related]
2. Speed of leukemia development and genetic diversity in xenograft models of T cell acute lymphoblastic leukemia.
Poglio S; Lewandowski D; Calvo J; Caye A; Gros A; Laharanne E; Leblanc T; Landman-Parker J; Baruchel A; Soulier J; Ballerini P; Clappier E; Pflumio F
Oncotarget; 2016 Jul; 7(27):41599-41611. PubMed ID: 27191650
[TBL] [Abstract][Full Text] [Related]
3. Preclinical efficacy of daratumumab in T-cell acute lymphoblastic leukemia.
Bride KL; Vincent TL; Im SY; Aplenc R; Barrett DM; Carroll WL; Carson R; Dai Y; Devidas M; Dunsmore KP; Fuller T; Glisovic-Aplenc T; Horton TM; Hunger SP; Loh ML; Maude SL; Raetz EA; Winter SS; Grupp SA; Hermiston ML; Wood BL; Teachey DT
Blood; 2018 Mar; 131(9):995-999. PubMed ID: 29305553
[TBL] [Abstract][Full Text] [Related]
4. The NOTCH1/CD44 axis drives pathogenesis in a T cell acute lymphoblastic leukemia model.
García-Peydró M; Fuentes P; Mosquera M; García-León MJ; Alcain J; Rodríguez A; García de Miguel P; Menéndez P; Weijer K; Spits H; Scadden DT; Cuesta-Mateos C; Muñoz-Calleja C; Sánchez-Madrid F; Toribio ML
J Clin Invest; 2018 Jul; 128(7):2802-2818. PubMed ID: 29781813
[TBL] [Abstract][Full Text] [Related]
5. [Establishment of a Patient-Derived T-Cell Acute Lymphoblastic Leukemia Xenograft Model in Novel Immunodeficient NCG Mice].
Jiang PJ; Dai XB; Kong XT; Xu ZQ; Yu H; Pang J; Xia W; Yu JH; Zhu GR; Tian F; Zhu XJ
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2023 Apr; 31(2):311-318. PubMed ID: 37096499
[TBL] [Abstract][Full Text] [Related]
6. IL-7R is essential for leukemia-initiating cell activity of T-cell acute lymphoblastic leukemia.
González-García S; Mosquera M; Fuentes P; Palumbo T; Escudero A; Pérez-Martínez A; Ramírez M; Corcoran AE; Toribio ML
Blood; 2019 Dec; 134(24):2171-2182. PubMed ID: 31530562
[TBL] [Abstract][Full Text] [Related]
7. The first Japanese biobank of patient-derived pediatric acute lymphoblastic leukemia xenograft models.
Tanaka K; Kato I; Dobashi Y; Imai JI; Mikami T; Kubota H; Ueno H; Ito M; Ogawa S; Nakahata T; Takita J; Toyoda H; Ogawa C; Adachi S; Watanabe S; Goto H
Cancer Sci; 2022 Nov; 113(11):3814-3825. PubMed ID: 35879192
[TBL] [Abstract][Full Text] [Related]
8. Establishment of a high-fidelity patient-derived xenograft model for cervical cancer enables the evaluation of patient's response to conventional and novel therapies.
Liu L; Wu M; Huang A; Gao C; Yang Y; Liu H; Jiang H; Yu L; Huang Y; Wang H
J Transl Med; 2023 Sep; 21(1):611. PubMed ID: 37689699
[TBL] [Abstract][Full Text] [Related]
9. PDX models recapitulate the genetic and epigenetic landscape of pediatric T-cell leukemia.
Richter-Pechańska P; Kunz JB; Bornhauser B; von Knebel Doeberitz C; Rausch T; Erarslan-Uysal B; Assenov Y; Frismantas V; Marovca B; Waszak SM; Zimmermann M; Seemann J; Happich M; Stanulla M; Schrappe M; Cario G; Escherich G; Bakharevich K; Kirschner-Schwabe R; Eckert C; Muckenthaler MU; Korbel JO; Bourquin JP; Kulozik AE
EMBO Mol Med; 2018 Dec; 10(12):. PubMed ID: 30389682
[TBL] [Abstract][Full Text] [Related]
10. Spleen plays a major role in DLL4-driven acute T-cell lymphoblastic leukemia.
Xiong H; Mancini M; Gobert M; Shen S; Furtado GC; Lira SA; Parkhurst CN; Garambois V; Brengues M; Tadokoro CE; Trimarchi T; Gómez-López G; Singh A; Khiabanian H; Minuzzo S; Indraccolo S; Lobry C; Aifantis I; Herranz D; Lafaille JJ; Maraver A
Theranostics; 2021; 11(4):1594-1608. PubMed ID: 33408769
[TBL] [Abstract][Full Text] [Related]
11. A cross-standardized flow cytometry platform to assess phenotypic stability in precursor B-cell acute lymphoblastic leukemia (B-ALL) xenografts.
Rolf N; Liu LYT; Tsang A; Lange PF; Lim CJ; Maxwell CA; Vercauteren SM; Reid GSD
Cytometry A; 2022 Jan; 101(1):57-71. PubMed ID: 34128309
[TBL] [Abstract][Full Text] [Related]
12. Stability of patient-specific features of altered DNA replication timing in xenografts of primary human acute lymphoblastic leukemia.
Sasaki T; Rivera-Mulia JC; Vera D; Zimmerman J; Das S; Padget M; Nakamichi N; Chang BH; Tyner J; Druker BJ; Weng AP; Civin CI; Eaves CJ; Gilbert DM
Exp Hematol; 2017 Jul; 51():71-82.e3. PubMed ID: 28433605
[TBL] [Abstract][Full Text] [Related]
13. Targeting cytokine- and therapy-induced PIM1 activation in preclinical models of T-cell acute lymphoblastic leukemia and lymphoma.
De Smedt R; Morscio J; Reunes L; Roels J; Bardelli V; Lintermans B; Van Loocke W; Almeida A; Cheung LC; Kotecha RS; Mansour MR; Uyttebroeck A; Vandenberghe P; La Starza R; Mecucci C; Lammens T; Van Roy N; De Moerloose B; Barata JT; Taghon T; Goossens S; Van Vlierberghe P
Blood; 2020 May; 135(19):1685-1695. PubMed ID: 32315407
[TBL] [Abstract][Full Text] [Related]
14. T-cell acute lymphoblastic leukemia displays autocrine production of Interleukin-7.
Buffière A; Uzan B; Aucagne R; Hermetet F; Mas M; Nassurdine S; Aznague A; Carmignac V; Tournier B; Bouchot O; Ballerini P; Barata JT; Bastie JN; Delva L; Pflumio F; Quéré R
Oncogene; 2019 Nov; 38(48):7357-7365. PubMed ID: 31417180
[TBL] [Abstract][Full Text] [Related]
15. Therapeutic afucosylated monoclonal antibody and bispecific T-cell engagers for T-cell acute lymphoblastic leukemia.
Caracciolo D; Riillo C; Ballerini A; Gaipa G; Lhermitte L; Rossi M; Botta C; Duroyon E; Grillone K; Gallo Cantafio ME; Buracchi C; Alampi G; Gulino A; Belmonte B; Conforti F; Golino G; Juli G; Altomare E; Polerà N; Scionti F; Arbitrio M; Iannone M; Martino M; Correale P; Talarico G; Ghelli Luserna di Rorà A; Ferrari A; Concolino D; Sestito S; Pensabene L; Giordano A; Hildinger M; Di Martino MT; Martinelli G; Tripodo C; Asnafi V; Biondi A; Tagliaferri P; Tassone P
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33597219
[TBL] [Abstract][Full Text] [Related]
16. Therapeutic targeting of Notch signaling and immune checkpoint blockade in a spontaneous, genetically heterogeneous mouse model of T-cell acute lymphoblastic leukemia.
Gao J; Van Meter M; Hernandez Lopez S; Chen G; Huang Y; Ren S; Zhao Q; Rojas J; Gurer C; Thurston G; Kuhnert F
Dis Model Mech; 2019 Sep; 12(9):. PubMed ID: 31399482
[TBL] [Abstract][Full Text] [Related]
17. OBI-3424, a Novel AKR1C3-Activated Prodrug, Exhibits Potent Efficacy against Preclinical Models of T-ALL.
Evans K; Duan J; Pritchard T; Jones CD; McDermott L; Gu Z; Toscan CE; El-Zein N; Mayoh C; Erickson SW; Guo Y; Meng F; Jung D; Rathi KS; Roberts KG; Mullighan CG; Shia CS; Pearce T; Teicher BA; Smith MA; Lock RB
Clin Cancer Res; 2019 Jul; 25(14):4493-4503. PubMed ID: 31015346
[TBL] [Abstract][Full Text] [Related]
18. Establishment of a Patient-Derived Xenograft Tumor From Hepatitis C-Associated Liver Cancer and Evaluation of Imatinib Treatment Efficacy.
Nazzal M; Sur S; Steele R; Khatun M; Patra T; Phillips N; Long J; Ray R; Ray RB
Hepatology; 2020 Aug; 72(2):379-388. PubMed ID: 32356575
[TBL] [Abstract][Full Text] [Related]
19. Senescent stromal cell-induced divergence and therapeutic resistance in T cell acute lymphoblastic leukemia/lymphoma.
Habiel DM; Krepostman N; Lilly M; Cavassani K; Coelho AL; Shibata T; Elenitoba-Johnson K; Hogaboam CM
Oncotarget; 2016 Dec; 7(50):83514-83529. PubMed ID: 27835864
[TBL] [Abstract][Full Text] [Related]
20. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts.
Agnusdei V; Minuzzo S; Frasson C; Grassi A; Axelrod F; Satyal S; Gurney A; Hoey T; Seganfreddo E; Basso G; Valtorta S; Moresco RM; Amadori A; Indraccolo S
Leukemia; 2014 Feb; 28(2):278-88. PubMed ID: 23774673
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
